MEQUON, Wis. — Endece LLC, a biopharmaceutical company discovering and developing proprietary compounds for treating cancer, announced it has raised $1.2 million from private investors that it will use to further develop a compound it says could potentially turn off any kind of cancer cell.

The 5-year-old company has raised $15 million to date from its Wisconsin-based angel investors  plus an additional grant of $244,000 from the U.S. government’s Therapeutic Discovery Project and a $250,000 loan from the Wisconsin Department of Commerce Technology Venture Fund.